Authors who accepted an ePoster presentation are assigned to present their abstract live during one of five ePoster sessions, based on the final abstract category for each abstract. The ePosters will open at 2:30pm EST on Monday, February 8, 2021, and will remain open throughout WORLDSymposium 2021. Live Q&A will only occur during the assigned times as listed below.

All ePosters will be located in the Virtual Exhibit & ePoster Hall:

- **Basic Science Abstracts** will be presented on **Monday, February 8 from 2:30-3:30pm EST**
- **Translational Research Abstracts** will be presented on **Tuesday, February 9 from 2:30-3:30pm EST**
- **COVID-19 and Clinical Trials Abstracts** will be presented on **Wednesday, February 10 from 2:30-3:30pm EST**
- **Contemporary Forum Abstracts** will be presented on **Thursday, February 11 from 2:30-3:30pm EST**
- **Late-Breaking Abstracts** will be presented on **Friday, February 12 from 2:30-3:30pm EST**

Any poster numbers not listed will not be presented as the author is unable to attend the conference.

It is the policy of WORLDSymposium to publish all abstracts with the list of authors exactly as the abstract was submitted to WORLDSymposium. The first author of the submitted abstract will be listed as the presenting author on the Preliminary Program, Agenda, and Poster List.

### Monday, February 8 – ePoster Presentations

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Christiane Auray-Blais</td>
<td>The importance of mass spectrometry-based untargeted metabolomic approaches for biomarker discovery in lysosomal diseases</td>
</tr>
<tr>
<td>20</td>
<td>Claubia Bender</td>
<td>Effects of acid sphingomyelinase deficiency on oral health and craniofacial development</td>
</tr>
<tr>
<td>29</td>
<td>Daniela Castillo-Garcia</td>
<td>A novel nonsense LAMP2 variant associated with Danon disease in a pediatric male: A case report</td>
</tr>
<tr>
<td>30</td>
<td>Magdalena Cerón-Rodriguez</td>
<td>Female child with Fabry disease and two other genetic diseases: Spherocytosis, and congenital hypothyroidism - A case report</td>
</tr>
<tr>
<td>36</td>
<td>Chloe Christensen</td>
<td>Base editing of the N370S mutation in Gaucher disease skin fibroblasts</td>
</tr>
<tr>
<td>46</td>
<td>Simona D’Amore</td>
<td>Oral aspects of Gaucher disease: A case report</td>
</tr>
<tr>
<td>59</td>
<td>Tama Dinur</td>
<td>Impact of long-term enzyme replacement therapy on Lyso-Gb1 in patients with Gaucher disease: Comparison between 3 enzymatic formulations</td>
</tr>
<tr>
<td>66</td>
<td>Hassan Elsaid</td>
<td>Preliminary proteomic analysis reveals less abundant endosome-related proteins in gli knockout zebrafish (Danio rerio)</td>
</tr>
<tr>
<td>76</td>
<td>Chaitanya Gadepalli</td>
<td>Assessment and management of tracheomalacia in adult mucopolysaccharidosis type II: A case report</td>
</tr>
<tr>
<td>79</td>
<td>Srinitya Gannaharapu</td>
<td>Increased sulfatide disrupt mitochondrial function in Schwann and mesenchymal stromal cells in metachromatic leukodystrophy</td>
</tr>
<tr>
<td>80</td>
<td>Eric Joshua Garcia</td>
<td>RNA-seq analysis in three Gaucher disease sib-pairs discordant for Parkinson disease</td>
</tr>
<tr>
<td>96</td>
<td>Coy Heldermon</td>
<td>The beta-glucuronidase intracisternal A particle insertion model results in similar overall MPS VII phenotype as the single base deletion model when on the same C57BL/6j mouse strain</td>
</tr>
<tr>
<td>105</td>
<td>Ayuko Iverson</td>
<td>Clinical course of patients with Gaucher-associated Parkinson disease</td>
</tr>
<tr>
<td>111</td>
<td>Shih-hsin Kan</td>
<td>iPSC-derived human neural stem cells engraft in the brains of immunocompromised MPS I mice</td>
</tr>
<tr>
<td>114</td>
<td>Gustavo Maegawa</td>
<td>Psychosine-reducing molecules as therapies for globoid-cell leukodystrophy</td>
</tr>
<tr>
<td>115</td>
<td>Marcel André Kelkel</td>
<td>Lysosphingolipid detection using a non-invasive urine multiplex mass spectrometry approach for various lysosomal diseases</td>
</tr>
<tr>
<td>117</td>
<td>Aram Kim</td>
<td>Case report: Neurologic outcome after stem cell transplant in a patient with neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>124</td>
<td>Aditi Korlimarla</td>
<td>New insights into GI manifestations in late-onset Pompe disease: Lessons from the bench and bedside</td>
</tr>
<tr>
<td>125</td>
<td>Francyne Kubaski</td>
<td>Report of the first Brazilian patients with MPS IIID, with the observation of an unexpected increase of di-sulfated keratan sulfate</td>
</tr>
<tr>
<td></td>
<td>Name</td>
<td>Title</td>
</tr>
<tr>
<td>---</td>
<td>----------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>126</td>
<td>Francyne Kubaski</td>
<td>Screening for Niemann-Pick disease type C in Latin American using Lyso-SM-509 measurement in dried blood spots</td>
</tr>
<tr>
<td>127</td>
<td>Francyne Kubaski</td>
<td>Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency</td>
</tr>
<tr>
<td>136</td>
<td>Malte Lenders</td>
<td>Clinical impact of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease</td>
</tr>
<tr>
<td>140</td>
<td>Renuka Limgala</td>
<td>Mast cell stabilizers in management of IgE independent mast cell activation in infusion related reactions in patients with Fabry disease</td>
</tr>
<tr>
<td>145</td>
<td>Laura López de Frutos</td>
<td>Testing new biomarkers for lysosomal diseases</td>
</tr>
<tr>
<td>156</td>
<td>Angela McCall</td>
<td>Glycogen accumulation in smooth muscle in the Pompe disease mouse</td>
</tr>
<tr>
<td>159</td>
<td>Iskren Menkovic</td>
<td>Metabolomic study for the identification and characterization of novel Gaucher disease biomarkers</td>
</tr>
<tr>
<td>163</td>
<td>Hideto Morimoto</td>
<td>Reduction of heparan sulfate in the brain by pabinafusp alfa results in prevention of neurodegeneration and neurocognitive impairment in a mouse model of mucopolysaccharidosis type II</td>
</tr>
<tr>
<td>167</td>
<td>Joseph Muenzer</td>
<td>Genotype-phenotype findings in patients with mucopolysaccharidosis type II (MPS II): Data from the Hunter Outcome Survey</td>
</tr>
<tr>
<td>169</td>
<td>Behzad Najafian</td>
<td>Direct intercellular cross-correction of α-galactosidase-A deficiency in Fabry disease podocytes through tunneling nanotubes in a mixed cell culture model</td>
</tr>
<tr>
<td>172</td>
<td>Stephanie Newman</td>
<td>AAV9-hARSA decreases sulfatide accumulation in the aged ARSA-/- mouse model for metachromatic leukodystrophy</td>
</tr>
<tr>
<td>178</td>
<td>Andrew Oldham</td>
<td>MPS VII - extending the classical phenotype</td>
</tr>
<tr>
<td>182</td>
<td>Christopher Orsborne</td>
<td>Mosaic Fabry disease in a male presenting as hypertrophic cardiomyopathy: When enzyme levels are not enough</td>
</tr>
<tr>
<td>194</td>
<td>Gani Perez</td>
<td>RNA-seq analysis of GBA1 haploinsufficiency in brain samples from a Parkinson mouse model</td>
</tr>
<tr>
<td>200</td>
<td>Tyler Pierson</td>
<td>Human induced pluripotent stem cell models for CLN6</td>
</tr>
<tr>
<td>204</td>
<td>Michael Przybilla</td>
<td>Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis</td>
</tr>
<tr>
<td>205</td>
<td>Maria Alejandra Puentes-Tellez</td>
<td>A perspective on research, diagnosis, and management of lysosomal disorders in Colombia: An update</td>
</tr>
<tr>
<td>220</td>
<td>Richard Sam</td>
<td>Generating pluripotent stem-cell derived organoids to model Gaucher disease type 2</td>
</tr>
<tr>
<td>221</td>
<td>Gustavo Maegawa</td>
<td>CNS-targeting exosomes: A strategy to treat neurological lysosomal disorders</td>
</tr>
<tr>
<td>227</td>
<td>Ida Schwartz</td>
<td>Metab-Latam, four months of experience in the email discussion group</td>
</tr>
<tr>
<td>228</td>
<td>Ida Schwartz</td>
<td>A decade of molecular diagnosis of mucolipidosis II and III in Brazil: A pooled analysis of 32 patients</td>
</tr>
<tr>
<td>229</td>
<td>Ida Schwartz</td>
<td>Brazilian patients with Gaucher disease: Haplotype analysis</td>
</tr>
<tr>
<td>234</td>
<td>Allen Seylan</td>
<td>Novel regulatory function of GCN5L1 in lysosomal tubulation and biogenesis</td>
</tr>
<tr>
<td>240</td>
<td>Hatice Serap Sivri</td>
<td>Clinical characteristics and journey to diagnosis in patients with mucopolysaccharidosis type VII</td>
</tr>
<tr>
<td>243</td>
<td>Luis Soares</td>
<td>MPSBase: Comprehensive repository of differentially expressed genes for mucopolysaccharidases studies</td>
</tr>
<tr>
<td>251</td>
<td>Xinze Tan</td>
<td>Genotype-phenotype correlation of MPS II: A meta-analysis</td>
</tr>
<tr>
<td>255</td>
<td>Heidy Triana</td>
<td>Production and characterization of a recombinant alpha-N-acetyl glucosaminidase enzyme in the Pichia pastoris yeast</td>
</tr>
<tr>
<td>262</td>
<td>Gerda Cristal Villalba Silva</td>
<td>Neuro-networks investigating the neurological impairment of mucopolysaccharidases using a system biology approach</td>
</tr>
<tr>
<td>271</td>
<td>Matheus Wilke</td>
<td>Lyso-Gb1 levels in sisters with Gaucher disease type 1: A case report</td>
</tr>
<tr>
<td>273</td>
<td>Elizabeth Woo</td>
<td>Exploration of the role of whole exome sequencing variants in GBA1-associated Parkinson disease</td>
</tr>
<tr>
<td></td>
<td>Name</td>
<td>Abstract</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2</td>
<td>Alia Ahmed</td>
<td>MPS-specific physical symptom score (PSS) and adaptive functions in MPS IVA: A cross sectional study</td>
</tr>
<tr>
<td>8</td>
<td>Pam Andrews</td>
<td>Gathering evidence for newborn screening for Niemann-Pick disease type C</td>
</tr>
<tr>
<td>14</td>
<td>Rachel Bailey</td>
<td>Preclinical studies to support the intrathecal delivery of scAAV9/SUMF1 as a gene replacement therapy for multiple sulfatase deficiency</td>
</tr>
<tr>
<td>17</td>
<td>Roberto Barriales-Villa</td>
<td>Red Fabry: First year results of a Spanish pedigree project on Fabry disease</td>
</tr>
<tr>
<td>24</td>
<td>Nicholas Buss</td>
<td>Subretinal injection of RGX-381 to cynomolgus monkeys leads to supraphysiological levels of TPP1 in the eye</td>
</tr>
<tr>
<td>31</td>
<td>Xin Chen</td>
<td>Preclinical results in rodents strongly support clinical evaluation of scAAV9/MFSD8 as a potential gene therapy for CLN7 patients</td>
</tr>
<tr>
<td>38</td>
<td>Jennifer Cohen</td>
<td>Early diagnosis and treatment of infantile-onset Pompe disease via newborn screen</td>
</tr>
<tr>
<td>42</td>
<td>Jonathan Cooper</td>
<td>Devising effective enzyme replacement therapy for infantile onset neuronal ceroid lipofuscinosis (CLN1 disease)</td>
</tr>
<tr>
<td>53</td>
<td>John Day</td>
<td>A phase I/II open-label gene replacement clinical study for late onset Pompe Disease</td>
</tr>
<tr>
<td>54</td>
<td>Emily Daykin</td>
<td>DeepGestalt as a potential novel method to help discriminate between the Gaucher disease subtypes</td>
</tr>
<tr>
<td>62</td>
<td>Halil Dündar</td>
<td>The chemical chaperone 4-phenylbutyrate enhances alpha-galactosidase activity subsequent to stopcodon readthrough therapy with triamterene in Fabry disease R227X fibroblasts</td>
</tr>
<tr>
<td>68</td>
<td>Kristina Elvidge</td>
<td>A new initiative to tackle childhood dementia</td>
</tr>
<tr>
<td>78</td>
<td>Jaya Ganesh</td>
<td>A phase I/II multicenter gene therapy clinical study for Fabry disease</td>
</tr>
<tr>
<td>86</td>
<td>Jason Glanzman</td>
<td>A tractography tool that detects abnormalities in function in early metachromatic leukodystrophy</td>
</tr>
<tr>
<td>87</td>
<td>Shelly Goomber</td>
<td>Functional analysis and clinical curation of human acid alpha glucosidase (GAA) variants of unknown significance (VUS) screened from infants diagnosed with Pompe disease via newborn screening (NBS)</td>
</tr>
<tr>
<td>104</td>
<td>Jackie Imrie</td>
<td>International Niemann-Pick Disease Registry: Establishing worldwide inclusivity</td>
</tr>
<tr>
<td>118</td>
<td>Brittany Kimball</td>
<td>Comparison of long-term outcomes for survivors among hematopoietic stem cell transplant subjects using the Living Independently Study Assessment (LISA 2.0)</td>
</tr>
<tr>
<td>128</td>
<td>Francyne Kubaski</td>
<td>Newborn screening for six lysosomal diseases in Brazil: Pilot study update</td>
</tr>
<tr>
<td>132</td>
<td>Ashley Lahr</td>
<td>Analysis of parent perception of newborn screening for lysosomal disorders</td>
</tr>
<tr>
<td>148</td>
<td>Troy Lund</td>
<td>Effect of supraphysiological alpha-L-iduronidase (IDUA) expression on skeletal manifestations in mucopolysaccharidosis type I (MPS I) mice following ex vivo lentiviral vector transduction of hematopoietic stem cells</td>
</tr>
<tr>
<td>153</td>
<td>Margaux Masten</td>
<td>Epidemiology and access to expert care for the neuronal ceroid lipofuscinoses (NCLs)</td>
</tr>
<tr>
<td>154</td>
<td>Margaux Masten</td>
<td>Genotype-phenotype associations in CLN3 disease</td>
</tr>
<tr>
<td>155</td>
<td>Margaux Masten</td>
<td>Diagnostic confidence for CLN3 disease</td>
</tr>
<tr>
<td>175</td>
<td>Loreanne Oh</td>
<td>An algorithm for early diagnosis of mucopolysaccharidosis types IIIA and B</td>
</tr>
<tr>
<td>177</td>
<td>Torayuki Okuyama</td>
<td>Prevention of cognitive decline in patients with neuronopathic mucopolysaccharidosis type II treated by intracerebroventricular enzyme replacement therapy: 100-week results of an open-label phase 1/2 study</td>
</tr>
<tr>
<td>201</td>
<td>Nishitha Pillai</td>
<td>Evaluation of the effectiveness of hematopoietic stem cell transplantation in multiple sulfatase deficiency</td>
</tr>
<tr>
<td>207</td>
<td>Bryan Pukenas</td>
<td>Intracisternal administration of AAV9 gene therapies to target the central nervous system</td>
</tr>
<tr>
<td>208</td>
<td>Allegra Quadri</td>
<td>Population-based newborn screening for mucopolysaccharidosis type II: A single center’s experience</td>
</tr>
<tr>
<td>209</td>
<td>Julian Raiman</td>
<td>Update on safety and efficacy results for phase I/II trial of hydroxypropyl betacyclodextrin (HPâCD) administered intravenously in patients with Niemann-Pick disease type C1</td>
</tr>
<tr>
<td>Number</td>
<td>Author</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>226</td>
<td>Ida Schwartz</td>
<td>Phlebotomy in the treatment of hemosiderosis associated with Gaucher disease</td>
</tr>
<tr>
<td>235</td>
<td>Patty Sheehan</td>
<td>PR001 gene therapy increased GCase activity and improved neuronopathic Gaucher disease phenotypes</td>
</tr>
<tr>
<td>236</td>
<td>Patty Sheehan</td>
<td>PR001 gene therapy increased GCase activity and improved Gaucher disease type 1 phenotypes in mouse models</td>
</tr>
<tr>
<td>241</td>
<td>Miles Smith</td>
<td>Ex vivo lentiviral transduction of hematopoietic stem cells in mucopolysaccharidosis type II (MPS II) mice achieves high levels of systemic iduronate-2-sulfatase (IDS) enzyme activity and normalization of glycosaminoglycans (GAGs)</td>
</tr>
<tr>
<td>244</td>
<td>Chanan Stauffer</td>
<td>Dual therapy with migalastat and agalsidase-beta in a patient with Fabry disease with progressing hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>249</td>
<td>Dean Suhr</td>
<td>RANSIP newborn screening program: Working to bring early diagnostics, inclusion, and therapeutic access to metachromatic leukodystrophy patients</td>
</tr>
<tr>
<td>256</td>
<td>Michael Ueberall</td>
<td>Development of a Fabry disease screening tool for chronic pain patients - step 1: Categorization based on phenotypic risk profiles</td>
</tr>
<tr>
<td>260</td>
<td>Sarah Viall</td>
<td>Oregon's experience with newborn screening for Fabry, Gaucher, Pompe and mucopolysaccharidosis type I</td>
</tr>
<tr>
<td>264</td>
<td>Raymond Wang</td>
<td>First in-human intracisternal dosing of RGX-111 (adeno-associated virus 9/human α-L-iduronidase) for a 20-month-old child with mucopolysaccharidosis type I (MPS I): 1 year follow-up</td>
</tr>
<tr>
<td>278</td>
<td>Brianna Yund</td>
<td>A longitudinal report of neurocognitive abnormalities and their impact on quality of life in non-neuronopathic MPS II</td>
</tr>
<tr>
<td>281</td>
<td>Zion Zibly</td>
<td>Safety of intracisternal administration of AAV9 based gene therapy: Case series of PR001 in infants with Gaucher disease type 2</td>
</tr>
</tbody>
</table>
### Wednesday, February 10 – ePoster Presentations

<table>
<thead>
<tr>
<th>#</th>
<th>Author(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Carlos Acosta-Rodriguez-Bueno</td>
<td>Impact of SARS-CoV-2 pandemic on the care for patients with lysosomal disorders: The experience of a Mexican pediatric center</td>
</tr>
<tr>
<td>7</td>
<td>Marcio Andrade-Campos</td>
<td>Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic</td>
</tr>
<tr>
<td>11</td>
<td>Jane Ashworth</td>
<td>Assessment and outcomes of MPS patients having corneal transplantation</td>
</tr>
<tr>
<td>18</td>
<td>Michael Beck</td>
<td>Fabry Outcome Survey (FOS): Highlights from a 20-year patient registry of Fabry disease</td>
</tr>
<tr>
<td>23</td>
<td>Lindsey Bulleid</td>
<td>Appraisal of the use of FASTEX in clinical practice in the All Wales Inherited Metabolic Disease Service</td>
</tr>
<tr>
<td>25</td>
<td>Valeria Calbi</td>
<td>Lentiviral haematopoietic stem cell gene therapy for metachromatic leukodystrophy: Results in nine patients treated with a cryopreserved formulation of OTL-200</td>
</tr>
<tr>
<td>26</td>
<td>M. Camprodon</td>
<td>Characterization of surgical procedures in patients with mucopolysaccharidosis</td>
</tr>
<tr>
<td>27</td>
<td>Maria Domenica Cappellini</td>
<td>Impact of SARS-CoV-2 infection on Gaucher disease patients in Italy</td>
</tr>
<tr>
<td>28</td>
<td>Francesca Carubbi</td>
<td>Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease</td>
</tr>
<tr>
<td>37</td>
<td>Tzu-Hung Chu</td>
<td>First MPS case in Kingdom of Eswatini</td>
</tr>
<tr>
<td>39</td>
<td>Jennifer Coker</td>
<td>Phenotypic target organ and biomarker variation within a family with late-onset Fabry disease</td>
</tr>
<tr>
<td>40</td>
<td>Duncan Cole</td>
<td>Clinical outcomes in an adult patient with alpha-mannosidosis treated with velmanase alfa for 5 years</td>
</tr>
<tr>
<td>45</td>
<td>Kirsten Cowley</td>
<td>RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): A clinical program to address central nervous system manifestations</td>
</tr>
<tr>
<td>47</td>
<td>Amanda Daniel</td>
<td>Development and evaluation of a nurse-led Anderson-Fabry clinic in Wales</td>
</tr>
<tr>
<td>48</td>
<td>Amanda Daniel</td>
<td>The impact of the COVID-19 pandemic on patients with inherited metabolic conditions: A survey in Wales</td>
</tr>
<tr>
<td>52</td>
<td>James Davison</td>
<td>Mini-COMET study: Effects of repeat avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease (IOPD) who were previously treated with alglucosidase alfa</td>
</tr>
<tr>
<td>55</td>
<td>Emily de los Reyes</td>
<td>Single-dose AAV9-CLN6 gene transfer slows the decline in motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6: Interim results from phase 1/2 trial</td>
</tr>
<tr>
<td>58</td>
<td>Mazen Dimachkie</td>
<td>NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset Pompe disease (LOPD)</td>
</tr>
<tr>
<td>61</td>
<td>Christina Dumke</td>
<td>Clinical characterization and therapy discussion of the p.Asp313Tyr variant in GLA</td>
</tr>
<tr>
<td>63</td>
<td>Marina Dutra-Clarke</td>
<td>Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy</td>
</tr>
<tr>
<td>70</td>
<td>Ulla Feldt-Rasmussen</td>
<td>Long-term treatment with migalastat 150 mg every other day is associated with sustained cardiac efficacy and is well tolerated</td>
</tr>
<tr>
<td>71</td>
<td>Luca Fierro</td>
<td>Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York</td>
</tr>
<tr>
<td>74</td>
<td>Aline Frey</td>
<td>Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease</td>
</tr>
<tr>
<td>75</td>
<td>Francesca Fumagalli</td>
<td>Lentiviral hematopoietic stem and progenitor cell gene therapy provides durable clinical benefit in early-symptomatic early-juvenile metachromatic leukodystrophy</td>
</tr>
<tr>
<td>77</td>
<td>Chaitanya Gadepalli</td>
<td>Salford Mucopolysaccharidosis Airway Score (SMAS): A novel marker of the severity of the airway disease in adult mucopolysaccharidoses</td>
</tr>
<tr>
<td>82</td>
<td>Blake Gimbel</td>
<td>Does extending enzyme replacement therapy after transplant provide neurocognitive benefit in Hurler syndrome?</td>
</tr>
<tr>
<td>84</td>
<td>Roberto Giugliani</td>
<td>Exploration of the efficacy of pabinafusp-alfa (JR-141) on neurocognitive development in Hunter syndrome (MPS II): 52-week data from clinical trials in Japan and Brazil</td>
</tr>
<tr>
<td>No.</td>
<td>Author</td>
<td>Title</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>85</td>
<td>Roberto Giugliani</td>
<td>Natural history of Sanfilippo syndrome type B in young patients: Ongoing results from two large, prospective studies</td>
</tr>
<tr>
<td>93</td>
<td>Paul Harmatz</td>
<td>Design and preliminary results of a first-in-human, 24-week study of intravenous DNL310 (brain-penetrant IDS) in MPS II</td>
</tr>
<tr>
<td>95</td>
<td>Caroline Hastings</td>
<td>Update on phase I study to evaluate the single- and multipledose pharmacokinetics of intravenous hydroxypropyl betacyclodextrin (HPβCD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease</td>
</tr>
<tr>
<td>97</td>
<td>Nadene Henderson</td>
<td>Phenocopy of acropaesthesias complicating a Fabry disease diagnosis</td>
</tr>
<tr>
<td>98</td>
<td>Benoist Heron-Longe</td>
<td>The RETRIEVE Study: A natural history study of Gaucher disease type 2, and GM1 and GM2 gangliosidoses with early onset, in preparation of a clinical trial</td>
</tr>
<tr>
<td>101</td>
<td>Dafne Horovitz</td>
<td>Need leads to change: Transition to home infusion in Pompe disease in Brazil in the COVID-19 pandemic</td>
</tr>
<tr>
<td>102</td>
<td>Derralyn Hughes</td>
<td>Switching between ERT and SRT in patients with Gaucher disease: Data from the Gaucher Outcome Survey (GOS)</td>
</tr>
<tr>
<td>109</td>
<td>JoAnn Johnson</td>
<td>Long-term outcomes of patients with mucopolysaccharidosis type VI treated with galsulfase enzyme replacement therapy since infancy</td>
</tr>
<tr>
<td>112</td>
<td>Sanjana Kapoor</td>
<td>Hydroxychloroquine use and toxicity in patients with Fabry disease: A case series</td>
</tr>
<tr>
<td>116</td>
<td>Aram Kim</td>
<td>Mullen Scales of Early Learning (MSEL) and Bayley Scales of Infant and Toddler Development (BSID): Utility in assessing cognitive endpoints in MPS clinical trials</td>
</tr>
<tr>
<td>119</td>
<td>Virginia Kimonis</td>
<td>Safety and effectiveness of resistance training in patients with late-onset Pompe disease: A pilot study</td>
</tr>
<tr>
<td>122</td>
<td>Priya Kishnani</td>
<td>Mini-COMET study: Individual participant-level responses to treatment in patients with infantile-onset Pompe disease receiving repeated dose regimens of avalglucosidase alfa or alglucosidase alfa who were previously treated with alglucosidase alfa</td>
</tr>
<tr>
<td>133</td>
<td>Dawn Laney</td>
<td>Fabry disease and COVID-19: International expert recommendations for management based on real-world experience</td>
</tr>
<tr>
<td>135</td>
<td>Heather Lau</td>
<td>Disease characteristics, early effectiveness, and safety of vestronidase alfa for the treatment of mucopolysaccharidosis type VII (MPS VII) assessed in a novel, longitudinal, multicenter Disease Monitoring Program (DMP)</td>
</tr>
<tr>
<td>139</td>
<td>Daniel Lewi</td>
<td>Unravelling the differences between infantile Tay-Sachs and Sandhoff disease using the GM2 Disease Registry (GM2DR)</td>
</tr>
<tr>
<td>141</td>
<td>Ales Linhart</td>
<td>Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study</td>
</tr>
<tr>
<td>142</td>
<td>Bianca Link</td>
<td>Orthopedic manifestations in patients with mucopolysaccharidosis type II enrolled in the Hunter Outcome Survey</td>
</tr>
<tr>
<td>144</td>
<td>Mabel Lopez</td>
<td>Meaningful endpoints in clinical trials for Infantile Krabbe disease</td>
</tr>
<tr>
<td>146</td>
<td>Allan Lund</td>
<td>Evaluation of 2 patients with alpha-mannosidosidosis and history of conductive hearing impairment participating in a placebo-controlled, phase 3 program receiving velmanase alfa (human recombinant alpha-mannosidase)</td>
</tr>
<tr>
<td>147</td>
<td>Allan Lund</td>
<td>Effect of velmanase alfa (human recombinant alpha-mannosidase) enzyme-replacement therapy on quality of life and disease burden of patients with alpha-mannosidosidosis: Results from caregiver feedback</td>
</tr>
<tr>
<td>157</td>
<td>Atul Mehta</td>
<td>Long-term treatment of Gaucher disease with velaglucerase alfa in a cohort of patients from Paraguay</td>
</tr>
<tr>
<td>160</td>
<td>Habitha Mohammed Sulaiman</td>
<td>Ten years of Fabry disease in the Northern Irish population</td>
</tr>
<tr>
<td>161</td>
<td>Adriana Montano</td>
<td>Growth patterns in subjects with mucopolysaccharidosis type VII</td>
</tr>
<tr>
<td>162</td>
<td>Marta Morado</td>
<td>Persistent thrombocytopenia in Gaucher disease (GD): A case report</td>
</tr>
<tr>
<td>164</td>
<td>Joseph Muenzer</td>
<td>Comparison of cognitive function in siblings with neuronopathic mucopolysaccharidosis type II: Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>165</td>
<td>Joseph Muenzer</td>
<td>Long-term safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis type II: 2-year results from a phase 2/3 extension study</td>
</tr>
<tr>
<td>166</td>
<td>Joseph Muenzer</td>
<td>Single-arm, open-label, phase 2/3 substudy and extension evaluating safety and efficacy of intrathecal idursulfase-IT in patients younger than 3 years old with neuronopathic mucopolysaccharidosis type II</td>
</tr>
<tr>
<td>168</td>
<td>Nicole Muschol</td>
<td>Tralesinidase alfa (AX 250) enzyme replacement therapy for Sanfilippo syndrome type B</td>
</tr>
<tr>
<td>170</td>
<td>Behzad Najafian</td>
<td>Podocyte globotriaosylceramide (GL-3) content declines sharply within 5 months of agalsidase-β enzyme replacement treatment followed by a more gradual decline thereafter</td>
</tr>
<tr>
<td>176</td>
<td>Torayuki Okuyama</td>
<td>Drug delivery across the blood-brain barrier and resultant reduction of heparan sulfate in the cerebrospinal fluid in the patients with Hunter syndrome (MPS II): An integrated analysis of 25-week Japanese and Brazilian data on pabinafusp alfa (JR-141)</td>
</tr>
<tr>
<td>179</td>
<td>Andrew Oldham</td>
<td>Joint contractures and clonus as main indications for botulinum injections in adult patients with mucopolysaccharidoses: One centre experience</td>
</tr>
<tr>
<td>181</td>
<td>Cristol O'Loughlin</td>
<td>Caring for the caregivers: Sensory solutions to CTSD (Chronic Traumatic Stress Disorder)</td>
</tr>
<tr>
<td>183</td>
<td>Damara Ortiz</td>
<td>Transition to eliglustat in an individual with Gaucher disease type 1 on antipsychotic medication</td>
</tr>
<tr>
<td>191</td>
<td>Marc Patterson</td>
<td>Persistent effect of arimoclomol in patients with Nuemann-Pick disease type C: 12-month results from an open-label extension of a pivotal phase 2/3 study</td>
</tr>
<tr>
<td>203</td>
<td>Lynda Polgreen</td>
<td>Open-label clinical trial of anakinra in mucopolysaccharidosis type III: Interim analysis</td>
</tr>
<tr>
<td>210</td>
<td>Uma Ramaswami</td>
<td>Migalastat 150 mg every other day achieves bioequivalent exposures in adolescent and adult patients with Fabry disease</td>
</tr>
<tr>
<td>212</td>
<td>Shoshana Revel-Vilk</td>
<td>Study design: Development of an advanced machine learning algorithm for the early diagnosis of Gaucher disease using real-world data</td>
</tr>
<tr>
<td>214</td>
<td>Barry Rosenbloom</td>
<td>Hematologic malignancies and monoclonal gammopathy of undetermined significance in Gaucher disease type 1 patients in the International Collaborative Gaucher Group Gaucher Registry</td>
</tr>
<tr>
<td>216</td>
<td>Anne Rugari</td>
<td>KrabbeConnect patient journey map</td>
</tr>
<tr>
<td>217</td>
<td>Emory Ryan</td>
<td>COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic</td>
</tr>
<tr>
<td>219</td>
<td>Siddhee Sahasrabudhe</td>
<td>Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies</td>
</tr>
<tr>
<td>222</td>
<td>Jessica Scherr</td>
<td>Comparing developmental outcomes of children with CLN2 disease receiving cerliponase alfa to a natural history cohort</td>
</tr>
<tr>
<td>223</td>
<td>Raphael Schifffmann</td>
<td>Venglustom combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3</td>
</tr>
<tr>
<td>224</td>
<td>Angela Schulz</td>
<td>Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children younger than three years: Interim results from an ongoing clinical study</td>
</tr>
<tr>
<td>225</td>
<td>Marisa Schwab</td>
<td>In utero enzyme replacement therapy in fetuses with lysosomal diseases: A phase I clinical trial</td>
</tr>
<tr>
<td>230</td>
<td>Ida Schwartz</td>
<td>COVID-19 pandemic impact on Brazilian patients with lysosomal diseases: A patient’s perspective</td>
</tr>
<tr>
<td>231</td>
<td>Ida Schwartz</td>
<td>Impact of COVID-19 on treatment and follow-up in patients with selected lysosomal diseases in a Brazilian center</td>
</tr>
<tr>
<td>246</td>
<td>Karolina Stepien</td>
<td>Long-term outcomes in adult patients affected with fucosidosis: Psychosis as a new complication</td>
</tr>
<tr>
<td>247</td>
<td>Karolina Stepien</td>
<td>Cardiac surgical interventions in MPS I and VI patients in adulthood</td>
</tr>
<tr>
<td>248</td>
<td>Karolina Stepien</td>
<td>Prevalence of hearing problems in adult mucopolysaccharidosis</td>
</tr>
<tr>
<td>261</td>
<td>Amy Vierhile</td>
<td>Neuronal ceroid lipofuscinosis assessment utilizing virtual visits during a pandemic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>263</strong></td>
<td>Jesus Villarrubia</td>
<td>PREDIGA project: Preliminary results of the Spanish multicenter epidemiological and medical education project in acid sphingomyelinase deficiency disease (ASMD) and Gaucher disease (GD)</td>
</tr>
<tr>
<td><strong>265</strong></td>
<td>Melissa Wasserstein</td>
<td>Adults with chronic acid sphingomyelinase deficiency show significant visceral, pulmonary, and hematologic improvements after enzyme replacement therapy with olipudase-alfa: 1-year results of the ASCEND placebo-controlled trial</td>
</tr>
<tr>
<td><strong>266</strong></td>
<td>Michael West</td>
<td>Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype</td>
</tr>
<tr>
<td><strong>267</strong></td>
<td>Michael West</td>
<td>Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group</td>
</tr>
<tr>
<td><strong>270</strong></td>
<td>Matheus Wilke</td>
<td>Informing patients with rare diseases about COVID-19: Creation of the “Beto and the Coronavirus” booklet</td>
</tr>
<tr>
<td><strong>274</strong></td>
<td>Puriya Daniel Yazdanfard</td>
<td>Hearing loss in Fabry disease: A 16 year follow-up study of the Danish nationwide cohort</td>
</tr>
<tr>
<td>No.</td>
<td>Author(s)</td>
<td>Title</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5</td>
<td>Thomas Anderson</td>
<td>Pharmacokinetics properties of arimoclonol in Niemann-Pick disease type C: Modest and not clinically relevant effect of bodyweight or age</td>
</tr>
<tr>
<td>6</td>
<td>Allyson Anding</td>
<td>Miglustat does not enhance alglucosidase alfa or avalglucosidase alfa efficacy in Pompe mice</td>
</tr>
<tr>
<td>15</td>
<td>Eileen Baranowski</td>
<td>The qualitative development of the Pompe disease symptom scale and Pompe disease impact scale</td>
</tr>
<tr>
<td>21</td>
<td>Akhil Bhalla</td>
<td>Evaluation of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients</td>
</tr>
<tr>
<td>22</td>
<td>Rachel Botham</td>
<td>Engineering α-glucosidase to improve protein stability and cellular uptake for the potential treatment of Pompe disease</td>
</tr>
<tr>
<td>34</td>
<td>Yoonjin Cho</td>
<td>Clinical and numerical presentation of neurocognitive assessments for MPS II patients using the Bayley Scales of Infant Development- version 3 (BSID-III)</td>
</tr>
<tr>
<td>41</td>
<td>Fabrizio Comper</td>
<td>Generation of β-Glucocerebrosidase variants with increased half-life in human plasma for liver directed AAV gene therapy aimed at the treatment of Gaucher disease type 1</td>
</tr>
<tr>
<td>43</td>
<td>Fernanda Copeland</td>
<td>Uncovering the burden of Gaucher disease type 1: Patient perspectives on unaddressed symptoms, impact of disease, and the future of treatment</td>
</tr>
<tr>
<td>44</td>
<td>Romuald Corbau</td>
<td>FLT201: An AAV-mediated gene therapy for type 1 Gaucher disease designed to target difficult to reach tissues</td>
</tr>
<tr>
<td>49</td>
<td>Magdalena Daurer</td>
<td>Evaluation of CD45 positive cells in the brain and liver of NPC1-/- mice</td>
</tr>
<tr>
<td>50</td>
<td>Elin Haf Davies</td>
<td>Decentralised convenience: Digitised clinical assessment for impaired ambulation</td>
</tr>
<tr>
<td>51</td>
<td>Elin Haf Davies</td>
<td>Assessing paediatric feeding in lysosomal diseases using remote smartphone video technology</td>
</tr>
<tr>
<td>60</td>
<td>Marissa Donovan</td>
<td>SIG-005: Novel encapsulated non-viral cell-based therapy for MPS I</td>
</tr>
<tr>
<td>64</td>
<td>Florian Eichler</td>
<td>Initial signs and symptoms of metachromatic leukodystrophy: A caregiver perspective</td>
</tr>
<tr>
<td>67</td>
<td>Deborah Elstein</td>
<td>Psychometric validation of the Gaucher Disease Questionnaire (GDQ) to assess quality of life in patients with Gaucher disease</td>
</tr>
<tr>
<td>73</td>
<td>Brian Fluharty</td>
<td>SIG-007: Novel encapsulated non-viral cell-based therapy for Fabry disease</td>
</tr>
<tr>
<td>83</td>
<td>Jacinthe Gingras</td>
<td>HMI-202: A gene therapy development candidate for metachromatic leukodystrophy (MLD)</td>
</tr>
<tr>
<td>90</td>
<td>Lavesh Gwalani</td>
<td>Invariant natural killer T cell-mediated cytokine secretion is a potential biomarker to monitor the efficacy of treatment for Fabry disease</td>
</tr>
<tr>
<td>94</td>
<td>Hidehiko Hashimoto</td>
<td>Usefulness of hexose tetrasaccharide as a biomarker for monitoring glycogen accumulation in peripheral tissues and brain in Pompe disease</td>
</tr>
<tr>
<td>99</td>
<td>Ryo Higurashi</td>
<td>Phase I/II clinical trial design for a novel therapy for mucopolysaccharidosis type I with an intravenously administered blood-brain barrier-crossing enzyme (JR-171)</td>
</tr>
<tr>
<td>100</td>
<td>Max Hilz</td>
<td>Burden of illness of Fabry disease: A retrospective claims analysis of a German sickness fund database</td>
</tr>
<tr>
<td>103</td>
<td>Atsushi Imakiire</td>
<td>Non-clinical evaluation of a blood-brain barrier-penetrable a-N-acetylglucosaminidase in a mouse model of mucopolysaccharidosis type IIIB</td>
</tr>
<tr>
<td>106</td>
<td>Leslie Jacobsen</td>
<td>The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease</td>
</tr>
<tr>
<td>108</td>
<td>Franklin Johnson</td>
<td>Migalastat clinical dose is highly extracted by hemodialysis and hemodiafiltration</td>
</tr>
<tr>
<td>110</td>
<td>Simon Jones</td>
<td>Demographic and clinical characteristics of patients with metachromatic leukodystrophy in the United Kingdom: Interim results from an observational real-world study</td>
</tr>
<tr>
<td>123</td>
<td>Jennifer Klein</td>
<td>The Mucolipidosis Collaborative Research Network (MCRN)</td>
</tr>
<tr>
<td>129</td>
<td>Ian Kurashige</td>
<td>Enzyme replacement therapy treatment patterns and patient outcomes in late-onset Pompe disease</td>
</tr>
<tr>
<td>130</td>
<td>Kristin LaBounty Phillips</td>
<td>Co-creating a gene therapy clinical trial with GM2 gangliosidosis caregivers: A virtual approach to patient engagement</td>
</tr>
<tr>
<td>137</td>
<td>Daniel Lewi</td>
<td>Aparito's six year journey in lysosomal disorders</td>
</tr>
<tr>
<td>138</td>
<td>Daniel Lewi</td>
<td>The new normal: Smartphone technology and its impact on the logistics of healthcare</td>
</tr>
<tr>
<td>143</td>
<td>Tina Loeffler</td>
<td>Characterization of 4L/PS-NA mice for cytokine activity and neurodegeneration</td>
</tr>
<tr>
<td>151</td>
<td>Joe Marion</td>
<td>A disease progression model for trials in mucopolysaccharidosis type IIIA</td>
</tr>
<tr>
<td>152</td>
<td>Deborah Marsden</td>
<td>Significant unmet need in infants with mucopolysaccharidosis type VII and non-immune hydrops fetalis: A summary of cases</td>
</tr>
<tr>
<td>158</td>
<td>Eugen Mengel</td>
<td>Impacts and burden of Niemann-Pick disease type C: A patient and caregiver perspective</td>
</tr>
<tr>
<td>171</td>
<td>Marie-Laure Nevoret</td>
<td>RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): Interim results of an ongoing first in human trial</td>
</tr>
<tr>
<td>186</td>
<td>Francis Pang</td>
<td>Quality of life of patients with metachromatic leukodystrophy and their caregivers in the US, UK, Germany and France</td>
</tr>
<tr>
<td>187</td>
<td>Francis Pang</td>
<td>Health-related quality of life in metachromatic leukodystrophy based on a societal utility study in the UK</td>
</tr>
<tr>
<td>188</td>
<td>Tiffany Pang</td>
<td>Clinical utility of a sponsored gene panel testing program for pediatric epilepsy and CLN2 disease diagnosis: Results from 4246 tests</td>
</tr>
<tr>
<td>189</td>
<td>Kruti Patel</td>
<td>HMI-203: Investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome</td>
</tr>
<tr>
<td>190</td>
<td>Marc Patterson</td>
<td>Validation of a short-form 5-domain Niemann-Pick type C clinical severity scale (5-domain NPCCSS)</td>
</tr>
<tr>
<td>192</td>
<td>Erika Pearson</td>
<td>Development of a novel encapsulated non-viral cell-based therapy for MPS VI</td>
</tr>
<tr>
<td>196</td>
<td>M. Judith Peterschmitt</td>
<td>Oral venglustat in Parkinson disease patients with a GBA mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics</td>
</tr>
<tr>
<td>197</td>
<td>Nikolaj Petersen</td>
<td>Rescue of NPC1 protein by the heat shock response amplifier arimoclomol across multiple genotypes</td>
</tr>
<tr>
<td>198</td>
<td>Dawn Phillips</td>
<td>Characterizing expressive language skills in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective</td>
</tr>
<tr>
<td>199</td>
<td>Dawn Phillips</td>
<td>Characterizing visual function in children with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2): The caregiver perspective</td>
</tr>
<tr>
<td>211</td>
<td>Sujata Ravi</td>
<td>Development of a GLA nAb assay with a fully-human, neutralizing IgG4 positive control to characterize antibody response in Fabry disease patients</td>
</tr>
<tr>
<td>213</td>
<td>Camille Rochmann</td>
<td>A qualitative study of the experience of venglustat for patients with Gaucher disease type 3 (GD3) in LEAP: A phase II open-label, multicenter, multinational study</td>
</tr>
<tr>
<td>232</td>
<td>Guillermo Seratti</td>
<td>Clinical utility of a sponsored, no-cost skeletal dysplasia gene panel testing program: Results from 850 tests</td>
</tr>
<tr>
<td>233</td>
<td>Irene Serrano Gonzalo</td>
<td>New insights in the TRAZELGA project for the adult type 1 Gaucher disease patients treated with eliglustat follow-up</td>
</tr>
<tr>
<td>238</td>
<td>Akashdeep Singh</td>
<td>Diagnostic yield and clinical utility of genetic testing in children with seizure onset after two years of age: Update over 2 1/2-year program in Europe and the Middle East</td>
</tr>
<tr>
<td>239</td>
<td>Akashdeep Singh</td>
<td>Molecular basis of mucopolysaccharidosis type IVA (Morquio syndrome type A): A review and classification of GALNS gene variants and reporting of new variants</td>
</tr>
<tr>
<td>242</td>
<td>Sairei So</td>
<td>Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (IR-141): Phase III global clinical trial design</td>
</tr>
<tr>
<td>252</td>
<td>Satowa Tanaka</td>
<td>Non-clinical evaluation of a blood-brain barrier-penetrable N-sulfoglucoasamine sulfohydrolase in a mouse model of mucopolysaccharidosis type IIIA</td>
</tr>
<tr>
<td>254</td>
<td>Drew Tietz</td>
<td>SIG-018: Novel encapsulated non-viral cell-based therapy for MPS II</td>
</tr>
<tr>
<td>272</td>
<td>Tobias Willer</td>
<td>Development of a novel gene therapy for Fabry disease: Engineered alpha-galactosidase A transgene for improved stability</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>276</strong></td>
<td>Karen Yee</td>
<td>Assessment of cognitive development in patients with neuronopathic mucopolysaccharidosis type II treated with intrathecal idursulfase-IT using Projected Retained Ability Score (PRAS): A post hoc analysis</td>
</tr>
<tr>
<td><strong>277</strong></td>
<td>Karen Yee</td>
<td>Caregiver experiences of intrathecal idursulfase-IT treatment in pediatric patients with neuronopathic mucopolysaccharidosis type II</td>
</tr>
</tbody>
</table>
### Friday, February 12 – ePoster Presentations

<table>
<thead>
<tr>
<th>LB-02</th>
<th>Elizabeth Berry-Kravis</th>
<th>Evidence for long-term efficacy of intrathecal adrabetadex for the treatment of neurological decline in patients with Niemann-Pick disease, type C1</th>
</tr>
</thead>
<tbody>
<tr>
<td>LB-03</td>
<td>Shabnam Bhuiyan</td>
<td>Impact of COVID-19 on lysosomal disease patients</td>
</tr>
<tr>
<td>LB-05</td>
<td>Fabrice Camou</td>
<td>Gaucher disease: Final results of ELGlustat Patient Reported Outcomes (ELIPRO), a prospective and multicentric study</td>
</tr>
<tr>
<td>LB-06</td>
<td>Pierre Carlier</td>
<td>NEO1/NEO-EXT studies: Muscle MRI results in patients with Pompe disease after long-term avalglucosidase alfa treatment</td>
</tr>
<tr>
<td>LB-07</td>
<td>Jennifer Clarke Matthews</td>
<td>Murine models of lysosomal diseases exhibit differences in brain protein aggregation and neuroinflammation</td>
</tr>
<tr>
<td>LB-08</td>
<td>Tanya Collin-Histed</td>
<td>Development of quality of life measures in neuronopathic Gaucher disease: Qualitative research findings</td>
</tr>
<tr>
<td>LB-09</td>
<td>Maria de Castro</td>
<td>Updated results of Transpher B, a multicenter, single-dose, phase 1/2 clinical trial of ABO-101 gene therapy for Sanfilippo syndrome type B (MPS IIIb)</td>
</tr>
<tr>
<td>LB-10</td>
<td>Emily de los Reyes</td>
<td>An open-label, phase 1/2a, AAV9-CLN3 gene transfer clinical trial for juvenile neuronal ceroid lipofuscinosis</td>
</tr>
<tr>
<td>LB-11</td>
<td>Claudia Cozma</td>
<td>Lyso-sphingolipid biomarker profiles of PSAP-associated disorders</td>
</tr>
<tr>
<td>LB-12</td>
<td>Vivian Fernandez</td>
<td>New research examines the evolution of data sharing practices in natural history studies and patient registries among patient advocate leaders, industry and academia</td>
</tr>
<tr>
<td>LB-13</td>
<td>Veronica Ferrari</td>
<td>VCP mutants induce lysosomal damage and autophagy activation in amyotrophic lateral sclerosis (ALS)</td>
</tr>
<tr>
<td>LB-14</td>
<td>Claudia Cozma</td>
<td>Building a human metabolome reference with applications in discovering new biomarkers and affected pathways in lysosomal diseases</td>
</tr>
<tr>
<td>LB-16</td>
<td>Takahiro Fujii</td>
<td>Discovery &amp; characterization of a novel brain-penetrant glucosylceramide synthase inhibitor as a potential therapeutic for Gaucher disease</td>
</tr>
<tr>
<td>LB-17</td>
<td>Ana García-Collazo</td>
<td>Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of neuronopathic Gaucher disease</td>
</tr>
<tr>
<td>LB-18</td>
<td>Robert Gotschall</td>
<td>Mucolipidosis type II AAV9 gene therapy pilot study: In vivo safety of over-expressing modified GlcNAc-1-phosphotransferase (S153) in wild-type mice</td>
</tr>
<tr>
<td>LB-19</td>
<td>Jerry Harb</td>
<td>Weekly enzyme replace therapy reverses hypertrophic cardiomyopathy in two Pompe knock-in murine models</td>
</tr>
<tr>
<td>LB-21</td>
<td>Justin Hopkin</td>
<td>Understanding health insurance literacy and challenges in accessing health services in Niemann-Pick disease</td>
</tr>
<tr>
<td>LB-22</td>
<td>Claudia Cozma</td>
<td>Methods of monitoring of neuropathic Gaucher disease in CSF</td>
</tr>
<tr>
<td>LB-23</td>
<td>Margarita Ivanova</td>
<td>TRAP5b and RANKL/OPG predict bone pathology in patients with Gaucher disease</td>
</tr>
<tr>
<td>LB-24</td>
<td>Alyssa Johnson</td>
<td>SVIP is a molecular determinant of lysosomal dynamic stability, neurodegeneration and lifespan</td>
</tr>
<tr>
<td>LB-25</td>
<td>Adam Kanack</td>
<td>Prothrombotic phenotypes in a rat model of Fabry disease</td>
</tr>
<tr>
<td>LB-26</td>
<td>Jin Young Kim</td>
<td>Efficacy of a novel long-acting arylsulfatase B analog (HM15450) with subcutaneous administration in mucopolysaccharidosis type VI (MPS VI) mouse model</td>
</tr>
<tr>
<td>LB-27</td>
<td>Dawn Laney</td>
<td>Pregnancy outcomes in agalsidase beta-treated and untreated females with Fabry disease and their offspring: A Fabry pregnancy sub-registry and pharmacovigilance database 15-year retrospective study</td>
</tr>
<tr>
<td>LB-28</td>
<td>Heather Lau</td>
<td>Long-term renal efficacy and incidence of Fabry-associated clinical events in treatment-naive and enzyme replacement therapy-experienced female patients receiving migalastat for Fabry disease up to 8.5 years</td>
</tr>
<tr>
<td>LB-29</td>
<td>Lucia Lavalle</td>
<td>Chloroquine differential impact on lysosomal hydrolases</td>
</tr>
<tr>
<td>LB-30</td>
<td>Lin Liu</td>
<td>Phosphorylated acid beta-glucosidase (M011, GCaseM6P) enzyme replacement therapy, leads to better tissue distribution, cellular uptake and efficacy in the GaucherD409A mouse model compared to conventional alpha-mannosyl terminated acid beta-glucosidase</td>
</tr>
<tr>
<td>LB-31</td>
<td>Anna Luzzi</td>
<td>Immunophenotyping of patients with Sanfilippo syndrome reveals a deficiency in natural regulatory t cells that is reversed with anakinra</td>
</tr>
<tr>
<td>LB-33</td>
<td>Benedicta Marshall-Andrew</td>
<td>Maintaining access to clinical trials during the COVID-19 pandemic</td>
</tr>
<tr>
<td>LB-34</td>
<td>Toni Mathieson</td>
<td>Patient and family perspective of lysosomal disease clinical care and services in the UK</td>
</tr>
<tr>
<td>LB-35</td>
<td>Alexandra Morrison</td>
<td>Diagnosis of mucopolysaccharidoses in the UK</td>
</tr>
<tr>
<td>LB-36</td>
<td>Juana Navarrete</td>
<td>Use of biomarkers to follow up positive lysosomal diseases in newborn screening</td>
</tr>
<tr>
<td>LB-37</td>
<td>Alberto Ortiz</td>
<td>Stabilization of kidney function decline and cardiomyopathy in male patients with classic Fabry disease: A pre- vs. post-agalsidase beta treatment Fabry Registry analysis</td>
</tr>
<tr>
<td>LB-38</td>
<td>Saida Ortolano</td>
<td>Systemic treatment of Fabry disease using a novel AAV9 vector expressing α-Galactosidase A</td>
</tr>
<tr>
<td>LB-39</td>
<td>Cho Rong Park</td>
<td>Efficacy of a novel long-acting alpha-galactosidase A analog (HM15421) with subcutaneous administration in Fabry disease mouse model</td>
</tr>
<tr>
<td>LB-40</td>
<td>Natalia Pérez-Carmona</td>
<td>Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of Gaucher disease</td>
</tr>
<tr>
<td>LB-41</td>
<td>Eva Raebel</td>
<td>Understanding challenges for ultra-rare lysosomal diseases: Patient and caregiver experience of care and support through the disease journey</td>
</tr>
<tr>
<td>LB-42</td>
<td>Tiziana Rosa</td>
<td>Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of GLB1-related disorders</td>
</tr>
<tr>
<td>LB-43</td>
<td>Yuki Shiro</td>
<td>Differential impairment of CLN6's anti-aggregate activity as a pathogenic mechanism of CLN6 disease</td>
</tr>
<tr>
<td>LB-44</td>
<td>Dylan Simon</td>
<td>Bringing together all newborn screening stakeholders</td>
</tr>
<tr>
<td>LB-45</td>
<td>Dylan Simon</td>
<td>Working to ensure that every state screens for all RUSP conditions</td>
</tr>
<tr>
<td>LB-46</td>
<td>Volha Skrahina</td>
<td>Towards defining the dynamics of Lyso-Gb1 accumulation in Gaucher patients</td>
</tr>
<tr>
<td>LB-47</td>
<td>Miles Smith</td>
<td>Ex vivo lentiviral transduction of hematopoietic stem cells in mucopolysaccharidosis type II (MPS II) mice achieves high levels of systemic iduronate-2-sulfatase (IDS) enzyme activity and normalization of glycosaminoglycans (GAGs)</td>
</tr>
<tr>
<td>LB-48</td>
<td>Marie Szymanowski</td>
<td>First case of neutralizing anti-ERT (enzyme replacement therapy) antibodies in Gaucher disease (GD) in a 9-year-old child</td>
</tr>
<tr>
<td>LB-49</td>
<td>Daisy Tapia</td>
<td>Prevalence of small vessel disease in a Fabry disease cohort</td>
</tr>
<tr>
<td>LB-50</td>
<td>Kazuyoshi Tomita</td>
<td>A comparison of developmental trajectories in sibling cases with neuropathic MPS II receiving conventional and novel enzyme replacement therapies</td>
</tr>
<tr>
<td>LB-51</td>
<td>Christoph Wanner</td>
<td>Reduced delays in diagnosis of patients with Fabry disease over time: A Fabry Registry analysis of data (1985-2020) stratified by gender and phenotype</td>
</tr>
</tbody>
</table>